Selective Thyroid Hormone Receptor Agonists for Lipid Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing thyroid hormone receptor (THR) agonists effectively reduce cholesterol and serum lipid levels but cause deleterious cardiovascular side effects and suppress the thyroid hormone axis, leading to issues like tachycardia, arrhythmia, elevated blood pressure, heart failure, muscle metabolism changes, and bone loss.
Innovation Solution
Development of selective THR agonists that selectively activate THR pathways to reduce cholesterol and serum lipid levels while minimizing suppression of the thyroid hormone axis and associated side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing thyroid hormone receptor agonists are used to reduce cholesterol and serum lipid levels, then lipid metabolism is improved, but cardiovascular side effects and suppression of the thyroid hormone axis occur
Solution Approach 1:
The patent applies local quality by developing selective THR agonists that target specific tissue distributions of thyroid hormone receptors. By designing compounds with selective affinity for THR subtypes expressed in different tissues (e.g., liver, adipose, muscle), the invention achieves localized metabolic effects without system-wide cardiovascular toxicity or HPT axis suppression, thus resolving the contradiction between lipid improvement and cardiovascular harm
Solution Approach 2:
The patent employs parameter changes by modifying the chemical structure of thyroid hormone receptor agonists to alter their binding affinity, selectivity, and pharmacokinetic properties. Through systematic variation of molecular parameters (e.g., substituent groups, steric configurations), the invention creates compounds that activate THR pathways for lipid metabolism while changing parameters that prevent cardiovascular side effects and HPT axis suppression
2Reliability
If existing thyroid hormone receptor agonists are used to lower cholesterol levels, then hyperlipidemia is treated, but the thyroid hormone axis is suppressed
Solution Approach 1:
The patent applies segmentation by dividing the thyroid hormone receptor system into distinct functional components (different THR isoforms and tissue-specific receptor populations). By designing agonists that selectively activate specific segments of this system (e.g., THRα in liver vs. THRβ in other tissues), the invention achieves cholesterol reduction without suppressing the overall HPT axis, as each segment is activated independently and appropriately
3Reliability
If thyroid hormone receptor pathways are activated to reduce serum lipids, then metabolic health is improved, but muscle metabolism and bone health are adversely affected
Solution Approach 1:
The patent applies local quality by creating selective agonists that target tissue-specific THR distributions. By designing compounds with preferential affinity for THR subtypes in metabolically relevant tissues (liver, adipose) while avoiding activation of THR populations in muscle and bone, the invention achieves serum lipid reduction without the harmful effects on muscle metabolism and bone health
Data Source
AI summary
Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.